Since the last CCSG renewal, Development Funds have supported 1) the recruitment of ten outstanding early career investigators, 2) development of two new shared resources and implementation of eight new services in existing shared resources, and 3) partial funding for fourteen MD Anderson Multidisciplinary Research Program (MRP) awards. The $500,000 of CCSG support for faculty recruitment has leveraged over $5.0M in MD Anderson start-up packages and more than $29.6M in new extramural grants. MRP awards provide seed funding of $250,000 over 3 years for groups of three or more center members to support planning and development of P01, SPORE, and CPRIT multi-investigator grant applications. Since the inception of the program in 1997, MD Anderson has invested $11.2M in MRP grants. These awards have been associated with external peer-reviewed funding of more than $157M, representing a 14.1-fold return on investment. During the present grant cycle, 17 proposals have been supported with $625,000 from CCSG Development Funds matched approximately 5:1 with institutional funds. This investment of CCSG support has leveraged $18.6M in extramural funding to date, with $8.8M from Multi-PI awards and $9.8M from individual investigator awards that resulted from projects supported as part of an MRP. Development Funds supported establishing the Functional Genomics Core (FGC) and the Assessment, Intervention and Measurement (AIM) core. In the current CCSG application, Development Funds are requested to continue support for faculty recruitment and fund additional MRP awards. Support is also requested for four developing shared resources: the Oncology Research and Immuno-Monitoring Core (ORION), the Microbiome Core Facility, the Shared Decision Making (SDM) Core, and the Metabolomics Core. Development Funds to provide support for establishing new methods and implementing new technologies within the shared resources and to fund collaborative pilot projects within and between programs are also proposed.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016672-43S1
Application #
9997888
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Shafik, Hasnaa
Project Start
Project End
Budget Start
2019-07-01
Budget End
2020-06-30
Support Year
43
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Chang, Geraldine H; Kurzrock, Razelle; Tran, Lisa et al. (2018) TP53 mutations and number of alterations correlate with maximum standardized uptake value (SUVmax) determined by positron emission tomography/computed tomography (PET/CT) [18F] fluorodeoxyglucose (18F-FDG PET). Oncotarget 9:14306-14310
Abaza, Yasmin; Cortes, Jorge; Ravandi, Farhad et al. (2018) Prognostic significance of hyperdiploidy in adult acute myeloid leukemia. Am J Hematol 93:E357-E360
Ellrott, Kyle; Bailey, Matthew H; Saksena, Gordon et al. (2018) Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. Cell Syst 6:271-281.e7
White, Matthew C; Schroeder, Rebecca D; Zhu, Keyi et al. (2018) HRI-mediated translational repression reduces proteotoxicity and sensitivity to bortezomib in human pancreatic cancer cells. Oncogene 37:4413-4427
Abaza, Yasmin; Hidalgo-Lopez, Juliana E; Verstovsek, Srdan et al. (2018) Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activation. Leuk Res 73:78-85
McGrail, Daniel J; Federico, Lorenzo; Li, Yongsheng et al. (2018) Multi-omics analysis reveals neoantigen-independent immune cell infiltration in copy-number driven cancers. Nat Commun 9:1317
Li, Carrie J; Jiang, Changying; Liu, Yang et al. (2018) Pleiotropic Action of Novel Bruton's Tyrosine Kinase Inhibitor BGB-3111 in Mantle Cell Lymphoma. Mol Cancer Ther :
Morita, Kiyomi; Kantarjian, Hagop M; Wang, Feng et al. (2018) Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia. J Clin Oncol 36:1788-1797
Raber, Benjamin; Bea, Vivian J; Bedrosian, Isabelle (2018) How Does MR Imaging Help Care for My Breast Cancer Patient? Perspective of a Surgical Oncologist. Magn Reson Imaging Clin N Am 26:281-288
Li, Roger; Metcalfe, Michael J; Ferguson 3rd, James E et al. (2018) Effects of thiazolidinedione in patients with active bladder cancer. BJU Int 121:244-251

Showing the most recent 10 out of 12418 publications